Marina Konopleva

Title: Marina Konopleva: Innovator in Cancer Therapy

Introduction

Marina Konopleva is a prominent inventor based in Houston, TX (US), known for her significant contributions to cancer treatment. With a focus on innovative therapies, she has developed groundbreaking methods that aim to improve patient outcomes in oncology. Her work has led to the filing of 3 patents, showcasing her commitment to advancing medical science.

Latest Patents

One of her latest patents is titled "Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer." This invention is directed towards a combination therapy that involves a selective Bcl-2 inhibitor and a MEK inhibitor, specifically designed for patients suffering from cancer, such as acute myeloid leukemia. Another notable patent is "CDDO-compounds and combination therapies thereof," which discusses the use of CDDO-compounds in combination with other chemotherapeutic agents. This patent highlights how these compounds can induce and potentiate cytotoxicity and apoptosis in cancer cells, providing new avenues for cancer therapies and methods to treat graft versus host diseases.

Career Highlights

Throughout her career, Marina has worked with esteemed institutions, including Dartmouth College and the University of Texas System. Her research has significantly impacted the field of cancer therapy, and her innovative approaches continue to inspire future developments in medical treatments.

Collaborations

Marina has collaborated with notable colleagues, including Michael Andreeff and Michael B. Sporn, further enhancing her research and contributions to the field of oncology.

Conclusion

Marina Konopleva's work exemplifies the spirit of innovation in cancer treatment. Her patents and collaborations reflect her dedication to improving patient care and advancing medical research.